/
RSS Feed
CHARLES HICKS, Associate Professor Medicine, Duke University, Durham
REFERENCE: Lancet 2006; 368: 466-75
Results with a new antiretroviral agent, tipranavir, tested among patients who were resistant to standard therapies have been published in The Lancet. Charles Hicks of Duke University in North Carolina told Sarah Maxwell about the treatment responses they’ve reported and the potential role of this agent for treating late stages of HIV infection.
[audio:https://www.audiomedica.com/podcasting/global_health/060929charles_hicks.mp3]
Results with a new antiretroviral agent, tipranavir, tested among patients who were resistant to standard therapies have been published in The Lancet. Charles Hicks of Duke University in North Carolina told Sarah Maxwell about the treatment responses they’ve reported and the potential role of this agent for treating late stages of HIV infection.
